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Abstract 
Several signaling cascades are involved in cell death, with a significant amount of crosstalk 
between  them.  Despite  the  complexity  of  these  cascades  several  key  pro-survival  and 
pro-death players have been identified. These include PI3-kinase, AKT and caspase-3. Here we 
review the approaches used to date to perform molecular imaging of these important targets. 
We focus in particular on approaches that include the possibility of modulating the activity of 
these kinases and proteases in a theranostic approach. 
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Introduction 
Several techniques have been developed to im-
age cell death and viability. These include the detec-
tion of changes in the pharmacokinetics and distribu-
tion  of  exogenous  contrast  agents  (for  example  de-
layed gadolinium enhancement in the myocardium), 
and the detection of altered metabolic activity in tis-
sue (for example radiolabeled glucose uptake in tu-
mors). More recently, molecular imaging techniques 
have been developed to image the mechanism of cell 
death. Several ligands, most notably annexin V and 
synaptotagmin, that bind to the surface of apoptotic 
cells have been used to image apoptosis in vivo by 
MRI  and  SPECT  [1-5].  In  addition,  a  DNA-binding 
gadolinium  chelate  (Gd-TO)  has  been  developed  to 
specifically  image  necrotic  cell  death  in  vivo  [6,  7]. 
Imaging  the  intracellular  signaling  involved  in  cell 
death and survival, however, has proven more chal-
lenging.  Nevertheless,  several  novel  techniques  to 
image  key  players  in  cell  death/survival  signaling 
have been developed.  
Here we review recent progress in the molecular 
imaging of three central kinases/proteases involved 
in  cell  death  and  survival:  1)  phosphatidylinosi-
tol-3-kinase  (PI3-kinase  or  PI3K);  2)  the  ser-
ine/threonine kinase AKT and; 3) the cysteine prote-
ase  caspase-3.  Particular  emphasis  is  placed  on  the 
role  of  these  agents  in  cardiovascular  disease  and 
cancer. We use the term “theranostic” fairly broadly 
to include any construct that can be imaged noninva-
sively in vivo and can modulate the biological activity 
of a kinase/protease. In some cases the imaging lig-
and and the therapeutic moiety may thus be identical, 
and in other cases the imaging ligand may serve only 
as a delivery vehicle for a separate therapeutic moiety. 
The appeal of the latter type of constructs (diagnostic 
delivery  vehicle  with  attached  therapeutic)  lies  in 
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their breadth. A library of theranostic agents can be 
generated by attaching a variety of therapeutic moie-
ties  to  the  agent.  The  challenge  of  these  types  of 
theranostic  constructs  is  that  they  are  larger,  more 
complex, and require a stable release mechanism for 
the therapeutic. As discussed below, initial progress 
in the field has thus been made largely with the for-
mer type of theranostic constructs, where the imaging 
ligand serves a dual diagnostic and therapeutic pur-
pose.  
A Brief Overview of Cell Death/Survival 
Signaling 
Cells  can  die  via  apoptosis,  necrosis  and  au-
tophagy [8]. The signaling pathways involved in all 
three of these pathways are extremely complex and 
beyond the scope of this review. Moreover, a signifi-
cant amount of crosstalk exists between these path-
ways, producing a complex and interconnected sys-
tem  of  signals.  Nevertheless,  several  key  nodes  in 
these pathways have been identified including PI3K, 
AKT and caspase-3 (Figure 1).  
The PI3-kinases are a family of lipid kinases that 
are able to phosphorylate the 3-hydroxyl group of the 
phosphoinositidyl ring [9]. Three classes of PI3K have 
been described. Class 1A PI3K is the focus of this pa-
per and plays a major role in cell death and survival, 
as well as autophagy via mTOR signaling. Class 1A 
PI3K has a regulatory subunit (p85) and a catalytic 
subunit (p110). The activation of PI3K is produced by 
the binding of growth factors such as HER2, IGF and 
EGRF to their receptor tyrosine kinases. Activation of 
the receptor tyrosine kinases results in an interaction 
with the p85 regulatory subunit of PI3K and removes 
its  inhibitory  effect  on  the  p110  catalytic  subunit. 
Negative feedback from downstream molecules, and 
the activity of the tumor suppressor PTEN, keep PI3K 
activation in balance [10]. Class 2 PI3K are catalytic 
enzymes that function downstream to activated EGF 
receptors, play a role in cell death/survival, and have 
no  regulatory/adapter  subunit.  Class  3  PI3Ks,  like 
class  1,  contain  a  regulatory  (p150)  and  catalytic 
(Vps34, 100 kDa) subunit and play an important role 
in cellular autophagy.  
 
 
 
Figure 1: Schematic of principal cell death/survival pathways. 
 Theranostics 2012, 2(2) 
 
http://www.thno.org 
150 
Activation of PI3K produces a robust pro-growth 
and survival effect, principally by activating the ser-
ine/threonine kinase AKT [11]. The activation of PI3K 
converts  phosphatidylinositol-bisphosphate  (PIP2) 
into phosphatidylinositol-triphosphate (PIP3). This in 
turn recruits AKT and the kinase PDK-1 (phospho-
inositidyl dependent kinase 1) to the cell membrane, 
where  AKT  is  phosphorylated  and  activated.  Acti-
vated AKT exerts a myriad of effects on the cell: AKT 
stimulates protein synthesis and cell growth by acti-
vating  mTOR (mammalian target  of rapamycin). (It 
should be noted that mTOR plays a major role in au-
tophagy  signaling  and  thus  plays  a  highly  mul-
ti-faceted role in cell death). AKT promotes cellular 
proliferation  by  promoting  the  cell  cycle  proteins 
(c-Myc and cyclin D1) and inactivating the cell cycle 
inhibitors  (p27  and  p21).  Functioning  indirectly 
through  the  mTOR  complex  (mTORC1),  AKT  also 
regulates  cell  proliferation  and  hypertrophy.  AKT 
inhibits the pro-apoptotic genes (BAD and BIM) thus 
promoting cell survival [10-12].  
The pro-survival role of AKT in the cell is op-
posed by a family of cysteine-aspartate proteases, or 
caspases, which play a pivotal role in cell death by 
apoptosis [8]. Apoptosis can be initiated via an intrin-
sic  or  extrinsic  pathway,  with  different  initiator 
caspases involved. The intrinsic pathway typically is 
initiated  by  the  interaction  of  cytochrome  c  with 
caspase-9. This pathway plays a major role in cardi-
omyocyte death in ischemic injury. The extrinsic or 
death receptor pathway involves caspase-8 and plays 
an  important  role  in  inflammatory  conditions  and 
chemotherapy. Both the intrinsic and extrinsic apop-
totic  pathways  lead  to  the  activation  of  caspase-3, 
which is the principal effector or executioner caspase 
in the cell [8]. In addition to executing the apoptotic 
program, caspase-3 is able to cleave sarcomeric pro-
teins in the myocardium, leading to a loss of function 
independent of cell death [13].  
The  pivotal  role  played  by  PI3K,  AKT  and 
caspase-3 in cell death/survival has been shown  in 
transgenic animal models, by using chemical inhibi-
tors and by insights provided from genomic analysis 
of  human  cancer.  Reduced  PTEN  expression  and 
mutations in PIK3A (gene on chromosome 3 encoding 
for the p110 subunit) are found in numerous human 
cancers [10]. These tumor cells are resistant to apop-
tosis due to hyperactivity of the PI3K-AKT pathway. 
The activation of AKT, frequently observed in human 
tumor cells, can promote growth factor-mediated cell 
survival directly by inactivating several proapoptotic 
factors  (BAD,  procaspase-9  and  Forkhead/FKHR 
transcription  factors),  and  indirectly  by  activating 
transcription  factors  that  upregulate  anti-apoptotic 
genes (cyclic-AMP response element-binding protein 
(CREB), Nuclear Factor-κB).  
In  the  heart,  the  activation  of  the  PI3K/AKT 
cascade  by  IGF-1  has  a  profound  cardioprotective 
effect in acute ischemia [14]. Conversely, the inhibi-
tion of PI3K by wortmannin (Wm) promotes apopto-
sis and exacerbates cell death in the heart during is-
chemia [12]. Wm has been extensively  studied as a 
chemotherapeutic  agent  in  vitro,  and  recent  data 
show  that  it  also  exerts  a  robust  anti-inflammatory 
effect that may prove useful in rheumatological syn-
dromes  and  other  inflammatory  conditions  [10,  15, 
16]. The inhibition of caspase-3 can be achieved with 
small molecules and has been shown to be extremely 
cardioprotective in ischemia and heart failure [17-19]. 
Transient overexpression of AKT in the myocardium 
during ischemic injury is also highly protective [20]. 
Chronic  overexpression  of  AKT,  however,  leads  to 
excessive negative feedback of PI3K and is harmful 
[21]. This underscores the complexity of the signaling 
involved in cell death/survival and the need for novel 
imaging tools to better understand how to modulate 
these processes.  
Molecular Imaging of PI3-Kinase 
Numerous inhibitors of PI3K have been devel-
oped and are being studied in a variety of cancers [10]. 
Some  are  pure  PI3K  inhibitors,  while  others  inhibit 
both PI3K and mTOR. Conceivably, several of these 
inhibitors might be suitable ligands for imaging PI3K, 
but this will need to be established in future studies. 
The  greatest  experience  to  date  is  with  the  natural 
PI3K inhibitor Wortmannin. Wm is a steroid-like vi-
ridin metabolite derived from the fungus Penicillium 
wortmanni. It is a broad and powerful inhibitor of all 
classes of PI3K with an IC50 in the low nanomolar 
range.  Wm  irreversibly  inactivates  PI3K  through  a 
covalent interaction between C20 on its furan ring and 
a  lysine  residue  on  the  ATP  binding  pocket  of  the 
p110 catalytic subunit of PI3K [22]. Unmodified Wm, 
however, is not a useful ligand for either conventional 
or  theranostic  molecular  imaging.  It  is  highly  lipo-
philic, reacts extremely rapidly with both the cellular 
and non-cellular constituents of the blood, and has a 
very short blood half-life. Modified Wms have thus 
been developed to image and modulate PI3K activity 
in cancer and inflammation. 
Wm has been modified at both its C11 and C20 
positions  to  produce  a  library  of  theranostics.  The 
fluorochrome NBD, has been attached to the C11 po-
sition of Wm to yield Wm-NBD [23]. Like Wm, NBD 
is  a  small,  uncharged  and  lipophilic  material. 
Wm-NBD thus maintains the properties of Wm, in-
cluding its low nanomolar IC50 for PI3K. However, Theranostics 2012, 2(2) 
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the presence of NBD on Wm allows the intracellular 
fate and location of the construct to be imaged with 
fluorescence  and  immunohistochemical  techniques 
[23]. The modification of Wm at its C20 position inac-
tivates it. However, depending on the nature of the 
modification,  the  C20-modified  Wm  can  reactivate 
itself [24, 25]. These Wms are thus self-activating vi-
ridins (SAV). The nature of the C20 modification in-
fluences the rate of self-activation. With an N-methyl 
pyridine  at  C20,  the  half-time  of  Wm  formation  is 
approximately  2  hours.  With  an  alkyl  group  based 
tertiary amines at C20, the half-time is 8-10 hours [24, 
25]. While the IC50 of the alkyl C20 modified Wms is 
reduced slightly, the prolonged nature of their release 
produced  a  stronger  antiproliferative  effect  in  vitro 
than unmodified Wm [24, 25].  
Modification of Wm at C20 also allows it to be 
attached  to  a  fluorescently  labeled  dextran  chain. 
Modification  at  C20  thus  not  only  regulates 
self-activation but also produces a soluble Wm con-
struct with the biodistribution properties of the dex-
tran  chain.  In  vivo  imaging  with  this  theranostic 
platform has been performed with a C11 (NBD) and 
C20 (alkyl, 70 kDa dextran-Cy5.5) modified construct 
(Figure  2)  [25].  Intravital  microscopy  of  the  Cy5.5 
moiety showed that the agent moved from the vas-
cular to the interstitial compartments with a half-life 
of 1.3 hours (Figure 2).  
 
 
Figure 2: Theranostic imaging of PI3-kinase with a self-activating viridin (SAV). (A) The SAV consists of wortmannin modified at the C11 
and C20 positions. The modification at position C11 resulted in the addition of the fluorochrome, NBD, while position C20 (red arrow) 
is modified to allow self-activation and conjugation to a dextran chain. When the leaving group (R) at C20 is CH3, the self-activating 
construct (SAV) is formed. When R=H the construct is non-activating (NAV). (B) Uptake of injected SAV into the vascularized portions 
of an implanted xenograft tumor in a mouse [25]. Immunohistochemistry of NBD reveals that the accumulation of wortmannin correlates 
strongly with CD31 expression. (C) Mice injected with the SAV construct (blue line) showed a complete arrest in tumor growth, which 
was not seen with NAV or dextran. (D) Intravital microscopy of the Cy5.5 moiety revealed that the kinetics of SAV were dominated by 
the 70 kDa dextran chain. 4 minutes after injection the probe was exclusively intravascular, but by 24 hours it has accumulated robustly 
in the interstitial space. (white arrow = blood vessel) [25]. (E) Anti-inflammatory effects of SAV in a mouse asthma model [15]. 
Whole-body fluorescence tomography images of the thoracic region show differential protease activity in the lungs. Mice injected with 
SAV show a marked reduction in protease activity in the lungs. Reproduced with permission.  Theranostics 2012, 2(2) 
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Mice implanted with an A549 tumor xenograft 
and injected with 1mg/kg/day of the SAV construct 
showed a complete elimination of tumor growth [25]. 
This  was  not  seen  in  mice  injected  with  a 
non-activating Wm construct (NAV) or with dextran. 
The NBD moiety on the C11 position of the SAV con-
struct  showed  that  the  injected  theranostic  reached 
the  vascularized  portions  of  the  tumor,  where  the 
activated Wm-NBD was released and affected tumor 
growth (Figure 2) [25].  
Transgenic knockout mice lacking PI3K show a 
reduction in neutrophil and macrophage activity. In 
particular,  the  oxidative  burst  in  neutrophils  is 
markedly attenuated in these animals. The ability of 
the SAV Wm construct to modulate immune related 
diseases  has  been  shown  in  mouse  models  of  in-
flammatory  arthritis  and  asthma  [15,  16].  Mice  in-
jected with 0.75mg/kg/day of the construct did not 
develop arthritis in a serum transfer model, unlike the 
mice not injected with the agent [16]. Likewise, the 
administration of the SAV construct significantly re-
duced pulmonary inflammation in a murine asthma 
model (Figure 2) [15]. It should be noted that the in-
jected dose of SAV needed for immune modulation is 
significantly lower than that needed to exert an anti-
proliferative effect. This raises the possibility of using 
SAV as an anti-inflammatory agent and minimizing 
any deleterious effects in healthy tissues.  
The optical imaging approaches described above 
are extremely useful in the preclinical setting but have 
limited  translational  potential.  Nevertheless,  they 
demonstrate the potential of a PI3K theranostic and 
lay  down  a  pathway  towards  clinical  translation. 
Modification of the C11 position with a radioactive 
label such as 11C or 18F would result in a highly trans-
latable PET-detectable probe. (The specific activity of 
the agent would need to be tailored to the theranostic 
dose). Other PI3K inhibitors may likewise be suited to 
PET imaging. Ultimately, a probe that is able to dis-
tinguish  between  the  activated  and  non-activated 
forms of PI3K could prove most useful. Many routes 
to theranostic imaging of PI3K thus exist and could 
play an important role in a large variety of conditions.  
Molecular Imaging of AKT 
Molecular  imaging  of  AKT  in  vivo  has  been 
performed  in  mice  using  a  bioluminescent  reporter 
approach. Bioluminescent AKT reporters (BAR) con-
sist  of  the  AKTpep  and  FHA2  domains  of  AKT, 
flanked  on  either  side  by  the  N-terminal  and 
C-terminal  domains  of  firefly  luciferase  [26].  Phos-
phorylation of the AKTpep domain causes it to inter-
act with  the FHA2 domain, sterically hindering the 
formation of a functional luciferase (Figure 3). AKT 
activation thus decreases the luminescent signal from 
the construct and can be used to image AKT activa-
tion/deactivation in vitro and in mice in vivo (Figure 
3) [26, 27]. More recently a membrane bound version 
of this split reporter has been described [28]. This is 
based on the fact that the activation of AKT involves 
its translocation to the cell membrane. The modified 
AKT reporter has been reported to be more quantita-
tive and sensitive than the original construct [28].  
 
 
 
 
 
Figure 3: Bioluminescent AKT reporter (BAR). (A) The phos-
phorylation of AKT leads to a conformational change in the con-
struct and prevents the association of the N and C terminal do-
mains of the reporter [26]. Activation of AKT thus leads to a 
reduction in the signal. (B, C) Mouse implanted with xenografts 
transfected with the BAR construct. (B) Little signal is seen before 
treatment. (C) A large signal is seen in mice treated with the AKT 
inhibitor perifosine [26, 27]. Reproduced with permission [26, 27].  
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A  similar  approach  (conformation  dependent 
reporter complementation) has been used to image a 
variety of kinases [29-31], as well as proteases such as 
caspase-3 [32]. While extremely elegant, and of major 
utility  in  the  preclinical  arena,  the  translational  po-
tential  of  this  approach  is  unclear.  Conceivably  it 
might be possible for a clinically-detectable PET re-
porter to be used to report kinase activity, but this has 
yet  to  be  shown.  Theranostic  approaches  will  also 
need to be developed. While many challenges remain, 
the  central  importance  of  AKT  in  cell  growth  and 
signaling make the development of theranostic agents 
to this molecule highly appealing.  
Molecular Imaging of Caspase-3 
Caspase-3  is  the  key  effector  protease  of  the 
apoptotic  cascade.  Three  approaches  have  been  de-
veloped  to  image  caspase-3  including:  1)  reporter 
gene approaches, 2) activatable fluorochromes and, 3) 
radiolabeled caspase inhibitors [33]. Most of the re-
porter and activatable constructs developed are based 
on the cleavage of a peptide linker at the caspase-3 
recognition  site  DEVD  (Asp-Glu-Val-Asp)  [34-37]. 
This leads to conformational changes in the construct 
such as the dequenching of a flanking pair of fluoro-
chromes/quencher or the generation of a functional 
reporter [34-37]. To gain access to the cell these agents 
must incorporate a cell penetrating capability, such as 
the incorporation of a cell penetrating peptide. This 
elegant  approach  has  allowed  in  vivo  imaging  of 
caspase-3 activation to be performed in small animals 
and in structures such as the retina of the eye (Figure 
4) [34-37]. Several limitations of this approach, how-
ever,  bear  mention.  The  intracellular  trafficking  of 
these constructs is difficult to control and accumula-
tion in lysosomes may lead to non-specific activation 
[33]. Furthermore the other effector caspases (caspases 
6, 7) can also activate these probes to some degree, 
although less so than caspase-3. The largest limitation 
of optical based caspase-3 imaging, however, lies in 
the  limited  potential  for  translation.  The  use  of  a 
thymidine  kinase  PET  reporter  to  image  caspase-3 
activity in vivo has been attempted but was less sen-
sitive than the use of fluorescent and bioluminescent 
reporters (Figure 4) [35]. Nevertheless, this raises the 
possibility of improved and translatable PET reporter 
approaches being used in the future to image caspa-
se-3 activity.  
The use of small chemical inhibitors to directly 
image  caspase-3  provides  alternative  strategy  for 
clinical translation. The most commonly used ligands 
are the isatin (1H-indole-2,3-dione) sulfonamide ana-
logs [38-40], which have an IC50 for caspase-3 inhibi-
tion in the nanomolar range. Several 18F-labeled isatin 
analogues have been used to image caspase-3 activity 
in small animal models in vivo (Figure 4).  
 
 
 
 
Figure 4: Molecular imaging of caspase-3. (A, B) Rats injected with a 18F labeled isatin analog. PET imaging shows that the signal in the liver 
(arrow) is significantly higher in a rat treated with cycloheximide (B) than in an untreated control animal (A) [38]. (C) Apoptosis in a 
xenograft tumor (arrows) imaged with PET after chemotherapy and the injection of an 18F labeled isatin analog [39]. (D) Luciferase 
reporter activated by caspase-3 [35]. A xenograft tumor transfected with the reporter emits a low signal before chemotherapy and a 
robust signal after treatment. Reproduced with permission [35, 38, 39]. 
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Uptake of the agent was increased in a rat model 
of cycloheximide induced liver injury [38]. Likewise, 
uptake of the agent in tumor xenografts was two-fold 
higher 24 hours after chemotherapy than in control 
animals [39]. While extremely promising, these stud-
ies have raised some important issues. Firstly, a large 
amount of background uptake of the isatin probes is 
seen  in  the  liver  and  other  abdominal  organs.  Sec-
ondly, the magnitude of the target signal seen from 
the isatin probes is moderate. Strategies will thus need 
to be developed to amplify the signal generated by the 
isatin probes and reduce their background uptake. In 
addition a very low specific activity formulation will 
need to be used to give the agent at a theranostic dose. 
Despite these challenges, the initial experience with 
these agents demonstrates the feasibility of generating 
theranostic approaches to image/modulate caspase-3 
activity in vivo.  
Conclusion 
Molecular  imaging  of  cell  death  continues  to 
gain momentum. While the imaging of the intracel-
lular kinases and proteases involved in cell death is in 
its infancy, the preclinical feasibility and utility of this 
approach has been well demonstrated. Future work 
must now focus on the development of translatable 
platforms to image intracellular kinase/protease ac-
tivity  in  vivo.  In  addition  to  new  diagnostic  con-
structs, novel theranostic constructs will also need to 
be developed. While this is a formidable challenge it is 
also  one  that  promises  large  rewards  and  is  well 
worth pursuing.  
Abbreviations 
PI3K:  Phosphatidylinositol  3-kinase;  AKT:  Akt 
family serine/threonine protein kinase; Gd-TO: Gad-
olinium-Thiazole Orange chelate; HER2: Human Ep-
idermal Growth Factor Receptor 2; IGF: Insulin-like 
growth factor; EGFR: Epidermal Growth Factor Re-
ceptor; PTEN: Phosphatase and tensin homolog; PIP2: 
phosphatidylinositol-bisphosphate;  PIP3:  phosphati-
dylinositol-triphosphate;  PDK-1:  Phosphoinositide 
Dependent  Kinase  1;  BAD:  Bcl-2-associated  death 
promoter; mTOR: Mammalian Target of Rapamycin; 
Wm: Wortmannin; NBD: Nitro-benzoxadiazole. 
Acknowledgements 
This work was funded in part by the following 
NIH grants: R01HL093038. 
Conflict of Interest 
The authors have declared that no conflict of in-
terest exists. 
References 
1.  Hofstra L, Liem IH, Dumont EA, Boersma HH, van Heerde WL, 
Doevendans PA, et al. Visualisation of cell death in vivo in pa-
tients  with  acute  myocardial  infarction.  Lancet.  2000;  356: 
209-12. 
2.  Narula J, Acio ER, Narula N, Samuels LE, Fyfe B, Wood D, et al. 
Annexin-V imaging for noninvasive detection of cardiac allo-
graft rejection. Nat Med. 2001; 7: 1347-52. 
3.  Sosnovik DE, Schellenberger EA, Nahrendorf M, Novikov MS, 
Matsui T, Dai G, et al. Magnetic resonance imaging of cardio-
myocyte apoptosis with a novel magneto-optical nanoparticle. 
Magn Reson Med. 2005; 54: 718-24. 
4.  Zhao M, Beauregard DA, Loizou L, Davletov B, Brindle KM. 
Non-invasive detection of apoptosis using magnetic resonance 
imaging and a targeted contrast agent. Nat Med. 2001; 7: 1241-4. 
5.  Sosnovik DE, Garanger E, Aikawa E, Nahrendorf M, Figuiredo 
JL, Dai G, et al. Molecular MRI of cardiomyocyte apoptosis with 
simultaneous  delayed-enhancement  MRI  distinguishes  apop-
totic and necrotic myocytes in vivo: potential for midmyocar-
dial salvage in acute ischemia. Circ Cardiovasc Imaging. 2009; 
2: 460-7. 
6.  Garanger E, Hilderbrand SA, Blois JT, Sosnovik DE, Weissleder 
R, Josephson L. A DNA-binding Gd chelate for the detection of 
cell death by MRI. Chem Commun (Camb). 2009;: 4444-6. 
7.  Huang S, Chen HH, Yuan H, Dai G, Schuhle DT, Mekkaoui C, 
et  al.  Molecular  MRI  of  acute  necrosis  with  a  novel 
DNA-binding  gadolinium  chelate:  kinetics  of  cell  death  and 
clearance in infarcted myocardium. Circ Cardiovasc Imaging. 
2011; 4: 729-37. 
8.  Hotchkiss RS, Strasser A, McDunn JE, Swanson PE. Cell death. 
N Engl J Med. 2009; 361: 1570-83. 
9.  Cantley LC. The phosphoinositide 3-kinase pathway. Science. 
2002; 296: 1655-7. 
10.  Markman  B,  Dienstmann  R,  Tabernero  J.  Targeting  the 
PI3K/Akt/mTOR  pathway--beyond  rapalogs.  Oncotarget. 
2010; 1: 530-43. 
11.  Manning  BD,  Cantley  LC.  AKT/PKB  signaling:  navigating 
downstream. Cell. 2007; 129: 1261-74. 
12.  Matsui T, Nagoshi T, Rosenzweig A. Akt and PI 3-kinase sig-
naling in cardiomyocyte hypertrophy and survival. Cell Cycle. 
2003; 2: 220-3. 
13.  Communal C, Sumandea M, de Tombe P, Narula J, Solaro RJ, 
Hajjar  RJ.  Functional  consequences  of  caspase  activation  in 
cardiac  myocytes.  Proceedings  of  the  National  Academy  of 
Sciences of the United States of America. 2002; 99: 6252-6. 
14.  Li Q, Li B, Wang X, Leri A, Jana KP, Liu Y, et al. Overexpression 
of insulin-like growth factor-1 in mice protects from myocyte 
death  after  infarction,  attenuating  ventricular  dilation,  wall 
stress, and cardiac hypertrophy. J Clin Invest. 1997; 100: 1991-9. 
15.  Cortez-Retamozo  V,  Swirski  FK,  Waterman  P,  Yuan  H, 
Figueiredo JL, Newton AP, et al. Real-time assessment of in-
flammation and treatment response in a mouse model of aller-
gic airway inflammation. J Clin Invest. 2008; 118: 4058-66. 
16.  Stangenberg L, Ellson C, Cortez-Retamozo V, Ortiz-Lopez A, 
Yuan H, Blois J, et al. Abrogation of antibody-induced arthritis 
in  mice  by  a  self-activating  viridin  prodrug  and  association 
with impaired neutrophil and endothelial cell function. Arthri-
tis Rheum. 2009; 60: 2314-24. 
17.  Hayakawa Y, Chandra M, Miao W, Shirani J, Brown JH, Dorn 
GW,  2nd,  et  al.  Inhibition  of  cardiac  myocyte  apoptosis  im-
proves  cardiac  function  and  abolishes  mortality  in  the  peri-
partum cardiomyopathy of Galpha(q) transgenic mice. Circu-
lation. 2003; 108: 3036-41. 
18.  Holly TA, Drincic A, Byun Y, Nakamura S, Harris K, Klocke FJ, 
et al. Caspase inhibition reduces myocyte cell death induced by Theranostics 2012, 2(2) 
 
http://www.thno.org 
155 
myocardial ischemia and reperfusion in vivo. J Mol Cell Cardi-
ol. 1999; 31: 1709-15. 
19.  Yaoita H, Ogawa K, Maehara K, Maruyama Y. Attenuation of 
ischemia/reperfusion  injury  in  rats  by  a  caspase  inhibitor. 
Circulation. 1998; 97: 276-81. 
20.  Matsui T, Tao J, del Monte F, Lee KH, Li L, Picard M, et al. Akt 
activation preserves cardiac function and prevents injury after 
transient cardiac ischemia in vivo. Circulation. 2001; 104: 330-5. 
21.  Nagoshi T, Matsui T, Aoyama T, Leri A, Anversa P, Li L, et al. 
PI3K rescues the detrimental effects of chronic Akt activation in 
the  heart  during  ischemia/reperfusion  injury.  J  Clin  Invest. 
2005; 115: 2128-38. 
22.  Wymann  MP,  Bulgarelli-Leva  G,  Zvelebil  MJ,  Pirola  L, 
Vanhaesebroeck B, Waterfield MD, et al. Wortmannin inacti-
vates  phosphoinositide  3-kinase  by  covalent  modification  of 
Lys-802, a residue involved in the phosphate transfer reaction. 
Mol Cell Biol. 1996; 16: 1722-33. 
23.  Barnes KR, Blois J, Smith A, Yuan H, Reynolds F, Weissleder R, 
et al. Fate of a bioactive fluorescent wortmannin derivative in 
cells. Bioconjug Chem. 2008; 19: 130-7. 
24.  Blois J, Yuan H, Smith A, Pacold ME, Weissleder R, Cantley LC, 
et al. Slow self-activation enhances the potency of viridin pro-
drugs. J Med Chem. 2008; 51: 4699-707. 
25.  Smith A, Blois J, Yuan H, Aikawa E, Ellson C, Figueiredo JL, et 
al. The antiproliferative cytostatic effects of a self-activating vi-
ridin prodrug. Mol Cancer Ther. 2009; 8: 1666-75. 
26.  Zhang L, Lee KC, Bhojani MS, Khan AP, Shilman A, Holland 
EC, et al. Molecular imaging of Akt kinase activity. Nat Med. 
2007; 13: 1114-9. 
27.  Zhang L, Bhojani MS, Ross BD, Rehemtulla A. Molecular im-
aging of protein kinases. Cell Cycle. 2008; 7: 314-7. 
28.  Zhang L, Bhojani MS, Ross BD, Rehemtulla A. Enhancing Akt 
imaging  through  targeted  reporter  expression.  Mol  Imaging. 
2008; 7: 168-74. 
29.  Khan  AP,  Contessa  JN,  Nyati  MK,  Ross  BD,  Rehemtulla  A. 
Molecular imaging of epidermal growth factor receptor kinase 
activity. Anal Biochem. 2011; 417: 57-64. 
30.  Nyati S, Schinske K, Ray D, Nyati M, Ross BD, Rehemtulla A. 
Molecular Imaging of TGFbeta-Induced Smad2/3 Phosphory-
lation Reveals a Role for Receptor Tyrosine Kinases in Modu-
lating TGFbeta Signaling. Clin Cancer Res. 2011; 17: 7424-39. 
31.  Zhang L, Virani S, Zhang Y, Bhojani MS, Burgess TL, Coxon A, 
et al. Molecular imaging of c-Met tyrosine kinase activity. Anal 
Biochem. 2011; 412: 1-8. 
32.  Bhojani MS, Nyati MK, Zhao L, Normolle DP, Ross BD, Law-
rence TS, et al. Molecular imaging of akt enables early predic-
tion of response to molecular targeted therapy. Transl Oncol. 
2011; 4: 122-5. 
33.  Niu G, Chen X. Apoptosis imaging: beyond annexin V. J Nucl 
Med. 2010; 51: 1659-62. 
34.  Maxwell D, Chang Q, Zhang X, Barnett EM, Piwnica-Worms D. 
An  improved  cell-penetrating,  caspase-activatable, 
near-infrared fluorescent peptide for apoptosis imaging. Bio-
conjug Chem. 2009; 20: 702-9. 
35.  Ray P, De A, Patel M, Gambhir SS. Monitoring caspase-3 acti-
vation with a multimodality imaging sensor in living subjects. 
Clin Cancer Res. 2008; 14: 5801-9. 
36.  Zhang F, Zhu L, Liu G, Hida N, Lu G, Eden HS, et al. Multi-
modality  imaging  of  tumor  response  to  doxil.  Theranostics. 
2011; 1: 302-9. 
37.  Barnett EM, Zhang X, Maxwell D, Chang Q, Piwnica-Worms D. 
Single-cell  imaging  of  retinal  ganglion  cell  apoptosis  with  a 
cell-penetrating, activatable peptide probe in an in vivo glau-
coma model. Proc Natl Acad Sci U S A. 2009; 106: 9391-6. 
38.  Chen DL, Zhou D, Chu W, Herrbrich PE, Jones LA, Rothfuss 
JM, et al. Comparison of radiolabeled isatin analogs for imaging 
apoptosis with positron emission tomography. Nucl Med Biol. 
2009; 36: 651-8. 
39.  Nguyen  QD,  Smith  G,  Glaser  M,  Perumal  M,  Arstad  E, 
Aboagye  EO.  Positron  emission  tomography  imaging  of 
drug-induced  tumor  apoptosis  with  a  caspase-3/7  specific 
[18F]-labeled  isatin  sulfonamide.  Proc  Natl  Acad  Sci  U  S  A. 
2009; 106: 16375-80. 
40.  Podichetty  AK,  Wagner  S,  Schroer  S,  Faust  A,  Schafers  M, 
Schober O,  et al.  Fluorinated isatin  derivatives.  Part 2. New 
N-substituted 5-pyrrolidinylsulfonyl isatins as potential tools 
for molecular imaging of caspases in apoptosis. J Med Chem. 
2009; 52: 3484-95.  